For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Biomanufacturing is a type of manufacturing or biotechnology that utilizes biological systems to produce commercially important biomaterials and biomolecules for use in medicines, food and beverage processing, and industrial applications. Biomanufacturing products are recovered from natural sources, such as blood, or from cultures of microbes, animal cells, or plant cells grown in specialized equipment. The biomanufacturing industry worldwide is currently witnessing immense technological transformations, giving rise to next generation biomanufacturing products. The global next-generation biomanufacturing market is projected to rise by USD 13.9 billion by 2029, according to the latest market study results. It is anticipated to expand at a CAGR of 8.7 percent during the forecast period.
The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global next-generation biomanufacturing market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors' approaches.
This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the workflow, medical application, end user, and region. The global market for next-generation biomanufacturing can be segmented by workflow: continuous upstream products, downstream biomanufacturing, single-use upstream products. The continuous upstream products segment is estimated to account for the largest share of the global next-generation biomanufacturing market. Next-generation biomanufacturing market is further segmented by medical application: hormones, monoclonal antibodies, recombinant proteins, vaccines, others. The monoclonal antibodies segment held the largest revenue share in 2022. Based on end user, the next-generation biomanufacturing market is segmented into: biopharmaceutical companies, CMOs and CDMOs, research institutions, others. Globally, the biopharmaceutical companies segment made up the largest share of the next-generation biomanufacturing market. On the basis of region, the next-generation biomanufacturing market also can be divided into: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America. North America was the largest contributor to the global next-generation biomanufacturing market in 2022.
The continuous upstream products market is further segmented into bags and containers, bioreactors and fermenters, biosafety cabinets, cell culture products, filtration systems, incubators, mixing system, sterilizers, others. The bioreactors and fermenters segment held the largest share of the global next-generation biomanufacturing market in 2022 and is anticipated to hold its share during the forecast period. Furthermore, the single-use upstream products market has been categorized into bags and containers, bioreactors, mixing systems, sensors and probes, tubing and connectors. In 2022, the bags and containers segment made up the largest share of revenue generated by the next-generation biomanufacturing market. The downstream biomanufacturing market is further divided into chromatography systems, filtration systems, instruments and accessories, membrane adsorbers, single-use equipment and accessories. Among these, the filtration systems segment was accounted for the highest revenue generator in 2022.
Market Segmentation
By workflow: continuous upstream products, downstream biomanufacturing, single-use upstream products
By medical application: hormones, monoclonal antibodies, recombinant proteins, vaccines, others
By end user: biopharmaceutical companies, CMOs and CDMOs, research institutions, others
By region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America
The report has also analysed the competitive landscape of the global next-generation biomanufacturing market with some of the key players being bbi-biotech GmbH, Danaher Corporation, Donaldson Company, Inc. (Solaris Biotechnology Srl), Eppendorf AG, Esco Micro Private Limited, GEA Group AG, Getinge AB (Applikon Biotechnology B.V.), Meissner Filtration Products, Inc., Merck KGaA, PBS Biotech, Inc., Pierre Guerin SAS, Sartorius AG, Thermo Fisher Scientific Inc., ZETA GmbH, among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
Scope of the Report
- To analyze and forecast the market size of the global next-generation biomanufacturing market.
- To classify and forecast the global next-generation biomanufacturing market based on workflow, medical application, end user, region.
- To identify drivers and challenges for the global next-generation biomanufacturing market.
- To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global next-generation biomanufacturing market.
- To identify and analyze the profile of leading players operating in the global next-generation biomanufacturing market.
Why Choose This Report
- Gain a reliable outlook of the global next-generation biomanufacturing market forecasts from 2023 to 2029 across scenarios.
- Identify growth segments for investment.
- Stay ahead of competitors through company profiles and market data.
- The market estimate for ease of analysis across scenarios in Excel format.
- Strategy consulting and research support for three months.
- Print authentication provided for the single-user license.